Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 6 (2025)
https://www.jneonatalsurg.com

Stem Cell Therapy in Regenerative Medicine Current Progress, Challenges, and Future Prospects

Dr. Amit Kumar Dutta[1], Dr. Ch. Srinivasulu[2], Dr. M Sunanda[3], Dr. P. Vara Lakshmi[4], Dr. N. Baratha Jyothi[5]

[1]Professor & Head, Amity Institute of Biotechnology, Amity University, Jharkhand

[2]Associate Professor of Zoology, NRR Govt.Degree College (A), Mahabubabad. Telangana. 506 101

[3]Assistant Professor, Department of Zoology, SR&BGNR GOVERNMENT ARTS AND SCIENCE COLLEGE (A), KHAMMAM, TELANGANA

[4]Lecturer in Zoology, .N.R (A) College, Bhimavaram-534202,W.G Dist, A.P.

[5]Assistant Professor in Zoology, Maris Stella College (A) Vijayawada, A.P.

.Cite this paper as: Dr. Amit Kumar Dutta, Dr. Ch. Srinivasulu, Dr. M Sunanda, Dr. P. Vara Lakshmi, Dr. N. Baratha Jyothi, (2025) Stem Cell Therapy in Regenerative Medicine Current Progress, Challenges, and Future Prospects. *Journal of Neonatal Surgery*, 14 (6), 368-376.

ABSTRACT

Stem cell therapy has emerged as a cornerstone of regenerative medicine, offering revolutionary potential for the treatment of a myriad of degenerative diseases, injuries, and organ dysfunctions. The unique ability of stem cells to self-renew and differentiate into specialized cell types has enabled researchers and clinicians to explore novel therapeutic strategies aimed at restoring or replacing damaged tissues. Over the past two decades, significant advancements have been made in stem cell research, including the identification and classification of different types of stem cells such as embryonic stem cells (ESCs), adult stem cells (ASCs), and induced pluripotent stem cells (iPSCs). These developments have paved the way for promising clinical applications, including the regeneration of cardiac tissue post-myocardial infarction, spinal cord injury repair, and treatment of hematological disorders.

Despite these advancements, stem cell therapy faces numerous scientific, ethical, and regulatory challenges. Key hurdles include immune rejection, tumorigenicity, limited cell survival and integration, and ethical debates surrounding the use of ESCs. Moreover, translating laboratory findings into effective clinical therapies remains a complex and lengthy process that involves rigorous testing, standardization of protocols, and stringent regulatory oversight. Additionally, the scalability of stem cell production and ensuring reproducibility across diverse patient populations are major concerns that need to be addressed.

Nevertheless, the future prospects of stem cell therapy remain optimistic, driven by breakthroughs in gene editing technologies, 3D bioprinting, and organoid development. The convergence of stem cell biology with other fields such as nanotechnology, artificial intelligence, and personalized medicine is expected to enhance the precision and efficacy of regenerative treatments. Ongoing clinical trials and interdisciplinary research initiatives continue to bring stem cell-based interventions closer to routine clinical practice.

This paper aims to provide a comprehensive overview of the current state of stem cell therapy in regenerative medicine. It explores recent progress in stem cell research, discusses the major challenges hindering clinical translation, and highlights future directions that may shape the next generation of regenerative therapies. By synthesizing the latest scientific insights and technological innovations, this review seeks to contribute to a better understanding of stem cell therapy's transformative potential in modern medicine.

Keywords: *Stem cell therapy, regenerative medicine, pluripotent cells, tissue engineering, clinical applications, ethical challenges, iPSCs, future prospects.*

1. INTRODUCTION

Regenerative medicine represents one of the most promising and rapidly advancing frontiers in modern biomedical science, aiming to restore or establish normal function by repairing or replacing damaged tissues and organs (1). At the core of this transformative field lies stem cell therapy, an innovative approach that utilizes the unique biological capabilities of stem cells—namely, their potential for self-renewal and differentiation into various specialized cell types (2). Over the past two decades, stem cell research has significantly expanded our understanding of tissue development, disease mechanisms, and cellular regeneration, laying a strong foundation for therapeutic interventions across a broad spectrum of medical disciplines (3).



Figure 1 Trend of Stem Cell Therapy Publications (2010–2024)

Stem cells are undifferentiated biological cells that possess two critical properties: the ability to perpetually self-renew and the capacity to differentiate into one or more specialized cell types under appropriate physiological or experimental conditions (4). These fundamental characteristics render stem cells particularly valuable for regenerative applications. They are broadly classified into embryonic stem cells (ESCs), adult (or somatic) stem cells (ASCs), and induced pluripotent stem cells (iPSCs). ESCs, derived from the inner cell mass of the blastocyst, are pluripotent and can give rise to any cell type in the body (5). However, their use is often constrained by ethical concerns and the risk of teratoma formation. ASCs, such as mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs), are multipotent and present fewer ethical and immunological complications, though their regenerative potential is comparatively limited. iPSCs, created by reprogramming adult somatic cells to a pluripotent state, offer an ethically acceptable and patient-specific source of stem cells, revolutionizing personalized medicine and disease modeling.

The clinical applications of stem cell therapy are already being realized in various domains. Hematopoietic stem cell transplantation has long been a standard treatment for hematological malignancies and genetic blood disorders (6). Similarly, MSCs have been explored for their immunomodulatory and anti-inflammatory properties in the treatment of autoimmune diseases, graft-versus-host disease, and orthopedic injuries. Research has also advanced in using stem cells to repair cardiac tissue after myocardial infarction, regenerate neurons in neurodegenerative diseases such as Parkinson’s and Alzheimer’s, and treat type 1 diabetes through islet cell regeneration (7). These clinical milestones underscore the immense therapeutic potential of stem cells in restoring tissue function, enhancing healing, and even reversing disease progression.



Figure 2 Distribution of Stem Cell Types in Clinical Trials – Highlights which stem cell types are most researched.

Despite these promising developments, several formidable challenges hinder the full-scale integration of stem cell therapy into mainstream clinical practice. These challenges are multi-faceted and include scientific, technical, ethical, and regulatory issues. Scientifically, ensuring the survival, integration, and functional maturation of transplanted stem cells within host tissues remains a significant hurdle (8). Technically, scalable manufacturing, controlled differentiation, and precise delivery methods require further optimization. From a regulatory standpoint, stringent quality control, standardization of protocols, and long-term safety evaluations are essential to ensure efficacy and minimize adverse outcomes such as immune rejection or tumorigenicity (9). Moreover, ethical concerns—especially surrounding the use of human embryos in ESC research—and the commercialization of unproven stem cell therapies pose additional layers of complexity.

The ethical and societal implications of stem cell therapy are particularly noteworthy. While ESCs raise concerns about the destruction of human embryos, iPSCs and ASCs provide more ethically palatable alternatives, though they are not without limitations. The proliferation of unregulated stem cell clinics offering unproven and often unsafe treatments further complicates the field, underscoring the need for stricter global regulatory frameworks and public education.

Nevertheless, the future of stem cell therapy remains exceedingly bright. Emerging technologies such as CRISPR-Cas9 gene editing, 3D bioprinting, and organ-on-a-chip systems are poised to overcome existing barriers and enhance the precision and efficacy of stem cell-based treatments (10). Additionally, the convergence of stem cell biology with bioengineering, nanotechnology, and artificial intelligence is driving the development of next-generation regenerative therapies tailored to individual patients (11). These advancements may not only broaden the therapeutic scope of stem cell applications but also reduce costs, improve accessibility, and accelerate clinical translation.

This research paper aims to provide a comprehensive and critical overview of stem cell therapy in regenerative medicine, focusing on its current progress, clinical applications, underlying challenges, and potential future directions. By examining recent advancements in stem cell science and addressing the technical and ethical obstacles that persist, the paper endeavors to shed light on the transformative role of stem cells in modern medicine and their potential to redefine therapeutic paradigms (12). As research and innovation continue to accelerate, stem cell therapy stands at the cusp of delivering on its long-standing promise of healing and regeneration, offering new hope for patients worldwide.

2. CLASSIFICATION AND BIOLOGICAL PROPERTIES OF STEM CELLS

2.1 Embryonic Stem Cells (ESCs), Adult Stem Cells (ASCs), and Induced Pluripotent Stem Cells (iPSCs)

Stem cells are broadly categorized into three primary types based on their developmental origin and differentiation potential: embryonic stem cells (ESCs), adult stem cells (ASCs), and induced pluripotent stem cells (iPSCs). ESCs are derived from the inner cell mass of the pre-implantation blastocyst and exhibit pluripotency—the capacity to differentiate into nearly all cell types of the body. Despite their vast therapeutic potential, the use of ESCs remains ethically contentious due to the destruction of embryos during isolation.

Adult stem cells, or somatic stem cells, are found in various postnatal tissues, including bone marrow, adipose tissue, and the umbilical cord. These cells are typically multipotent, meaning they can differentiate into a limited range of cell types related to their tissue of origin. They are widely used in clinical practice due to fewer ethical concerns and lower immunogenicity.

Induced pluripotent stem cells (iPSCs) represent a transformative advancement in regenerative medicine. They are generated by reprogramming somatic cells—such as skin fibroblasts—into a pluripotent state through the introduction of specific transcription factors (e.g., Oct4, Sox2, Klf4, and c-Myc). iPSCs closely mimic the properties of ESCs without the associated ethical issues, making them highly valuable for patient-specific therapies, disease modeling, and drug discovery.



Figure 3 Therapeutic Focus Areas in Stem Cell Therapy – Identifies major disease targets.

2.2 Characteristics: Self-Renewal, Potency, and Differentiation

The fundamental biological hallmarks of stem cells include self-renewal, potency, and differentiation. Self-renewal refers to the ability of stem cells to proliferate indefinitely while maintaining their undifferentiated state. Potency defines the differentiation capacity of a stem cell, ranging from totipotent (capable of forming all embryonic and extraembryonic tissues), to pluripotent (forming all cell types of the three germ layers), to multipotent (restricted to specific lineages), and finally to unipotent (generating only one cell type) (13).

Differentiation is the process through which stem cells develop into specialized cells with distinct structures and functions. This process is tightly regulated by intrinsic genetic programs and extrinsic environmental cues, including growth factors, cytokines, and extracellular matrix components.

2.3 Sources and Isolation Techniques

Stem cells can be isolated from a variety of embryonic and adult sources. ESCs are typically obtained from surplus embryos generated during in vitro fertilization (IVF) procedures, while ASCs can be harvested from bone marrow, adipose tissue, peripheral blood, and umbilical cord blood. iPSCs are produced in vitro through epigenetic reprogramming of adult somatic cells using defined factors.

Isolation techniques vary depending on the source and desired cell population. Common methods include density gradient centrifugation, enzymatic tissue digestion, magnetic-activated cell sorting (MACS), and fluorescence-activated cell sorting (FACS) (14). Advances in stem cell isolation and culture techniques have significantly improved the yield, purity, and viability of stem cells for research and therapeutic purposes.



Figure 4 Sources of Stem Cells Used in Therapy – Provides a breakdown of cell sources.

3. CURRENT APPLICATIONS OF STEM CELL THERAPY IN REGENERATIVE MEDICINE

3.1 Hematopoietic and Mesenchymal Stem Cell Therapies

Hematopoietic stem cell transplantation (HSCT) remains one of the earliest and most successful clinical applications of stem cell therapy. It is widely employed in the treatment of hematologic malignancies, such as leukemia and lymphoma, as well as in inherited blood disorders like sickle cell anemia and thalassemia. Hematopoietic stem cells (HSCs) sourced from bone marrow, peripheral blood, or umbilical cord blood are capable of reconstituting the entire hematopoietic system following high-dose chemotherapy or radiation.

Mesenchymal stem cells (MSCs), typically derived from bone marrow, adipose tissue, and Wharton's jelly, have gained increasing interest for their immunomodulatory, anti-inflammatory, and regenerative properties. MSCs are being investigated in the treatment of graft-versus-host disease, Crohn's disease, osteoarthritis, and a range of other degenerative and inflammatory conditions (15). Their low immunogenicity also makes them suitable for allogeneic transplantation.

3.2 Applications in Cardiovascular, Neurological, and Musculoskeletal Disorders

Stem cell-based therapies are showing considerable promise in the regeneration of damaged cardiac tissue, particularly in patients recovering from myocardial infarction. Transplantation of autologous or allogeneic stem cells has been associated with improved cardiac function, angiogenesis, and reduced scar formation.



Figure 5 Key Challenges in Clinical Translation – Outlines critical hurdles.

In the field of neurology, stem cells are being explored for their potential to replace lost neurons, restore synaptic connections, and modulate neuroinflammation in disorders such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, and spinal cord injuries. Preclinical studies have demonstrated improved functional recovery, while early-phase clinical trials are ongoing.

In orthopedic medicine, stem cells are being used for the repair and regeneration of cartilage, bone, and tendon tissues. MSCs, in particular, have been applied in the treatment of joint degeneration, fractures, and sports injuries, offering alternatives to invasive surgical procedures.

3.3 Stem Cell Use in Autoimmune Diseases and Diabetes

Autoimmune diseases, characterized by aberrant immune responses against self-tissues, may benefit from the immunomodulatory effects of stem cells. MSCs have been shown to suppress pathogenic immune cells and promote regulatory immune pathways in diseases such as systemic lupus erythematosus, rheumatoid arthritis, and type 1 diabetes.

In diabetes research, especially type 1 diabetes, efforts are underway to generate insulin-producing pancreatic beta cells from ESCs and iPSCs. These cells have the potential to restore insulin production and glycemic control, offering a curative approach that may eventually replace lifelong insulin therapy (16). Ongoing clinical trials and preclinical studies continue to refine the protocols for differentiation, transplantation, and long-term functionality of these cells.



Figure 6 Funding Distribution for Stem Cell Research by Application – Illustrates where research funding is concentrated.

4. TECHNOLOGICAL ADVANCES DRIVING STEM CELL RESEARCH

4.1 Gene Editing and CRISPR-Cas9 in Stem Cell Engineering

Recent advancements in gene editing have significantly expanded the therapeutic potential of stem cells, particularly with the emergence of CRISPR-Cas9 technology. CRISPR-Cas9 enables precise, efficient, and targeted modifications within the genome, facilitating the correction of genetic mutations directly within stem cells. This has been instrumental in developing disease-specific stem cell models and designing personalized cell-based therapies (17). For instance, iPSCs generated from patients with monogenic disorders can be genetically corrected and differentiated into functional cells for autologous transplantation, minimizing the risk of immune rejection. Moreover, gene editing has been used to enhance the homing capacity, survival rate, and differentiation efficiency of transplanted stem cells, thus improving their regenerative capabilities. Despite these advancements, concerns regarding off-target effects and long-term safety remain, necessitating ongoing refinement and comprehensive preclinical evaluation.

4.2 3D Bioprinting and Scaffold-Based Tissue Regeneration

3D bioprinting has revolutionized the field of tissue engineering by allowing the fabrication of complex, patient-specific tissue constructs. This technology utilizes bioinks—comprising stem cells and biocompatible materials—to print layer-by-layer structures that mimic the architecture and function of native tissues. By providing precise spatial control over cell placement, 3D bioprinting promotes more effective cell-cell interactions and tissue maturation. Complementing this, scaffold-based strategies involve the use of natural or synthetic biomaterials to support stem cell adhesion, proliferation, and differentiation (18). Scaffolds serve as temporary matrices that guide the formation of new tissues until endogenous remodeling takes place. Together, these technologies are being explored for regenerating bone, cartilage, skin, and even whole organs. Their integration with stem cell biology offers a promising avenue for constructing vascularized, functional tissues for transplantation and disease modeling.



Figure 7 Growth of Stem Cell Clinical Trials (2010–2024) – Tracks expansion of clinical investigations.

4.3 Role of Nanotechnology and Organoids in Enhancing Stem Cell Efficacy

Nanotechnology plays a pivotal role in improving the precision and efficiency of stem cell-based therapies. Engineered nanomaterials—such as nanoparticles, nanofibers, and nanotubes—are used to deliver bioactive molecules, drugs, or genetic material directly to stem cells, thereby influencing their behavior and fate. Additionally, nanoscale scaffolds can replicate the native extracellular matrix, enhancing stem cell viability and tissue integration.

In parallel, organoids—miniature, self-organizing 3D structures derived from stem cells—have emerged as powerful models that recapitulate the architecture and function of human organs. Organoids derived from iPSCs or ESCs provide valuable platforms for studying human development, pathophysiology, and response to drugs in vitro (19). These technologies not only offer new insights into disease mechanisms but also reduce reliance on animal models and accelerate the preclinical testing of regenerative therapies.

5. CHALLENGES AND ETHICAL CONSIDERATIONS IN CLINICAL TRANSLATION

5.1 Scientific and Technical Limitations

Despite remarkable progress, the clinical application of stem cell therapies is fraught with scientific and technical challenges. One of the foremost concerns is tumorigenicity, particularly associated with pluripotent stem cells such as ESCs and iPSCs. If undifferentiated or improperly differentiated cells are transplanted, there is a risk of teratoma formation. Therefore, ensuring complete and directed differentiation prior to clinical use is essential.

Another critical issue is immune rejection, especially in allogeneic transplantation. While autologous therapies reduce immunological complications, they are not always feasible due to cost, time, or underlying genetic defects. Strategies such as HLA matching, immune tolerance induction, and gene-editing approaches to create hypoimmunogenic cells are currently being explored to address this barrier.

5.2 Regulatory and Standardization Issues

Bridging the gap between laboratory research and clinical application requires robust regulatory frameworks and standardized protocols. Variability in stem cell isolation, expansion, and differentiation methods can lead to inconsistent therapeutic outcomes. Regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have developed guidelines to evaluate the safety, efficacy, and quality of stem cell-based products (20). However, global disparities in regulatory standards continue to pose challenges. Establishing universally accepted Good Manufacturing Practices (GMP), validated potency assays, and long-term post-transplant monitoring is vital for ensuring the reproducibility and safety of stem cell therapies across clinical settings.

5.3 Ethical Concerns: Embryo Use, Informed Consent, and Unregulated Clinics

Ethical considerations remain central to the debate surrounding stem cell research and application. The use of human embryos for deriving ESCs raises moral objections related to the beginning of human life. Although iPSCs offer an ethically sound alternative, they do not completely eliminate ethical complexities, particularly concerning consent, ownership of biological material, and potential for misuse.

Another pressing concern is the proliferation of unregulated clinics offering unproven stem cell treatments, often under the guise of “innovative” or “personalized” therapies. These clinics frequently operate without appropriate oversight, placing patients at significant risk of harm. To combat this issue, stronger regulatory enforcement, international collaboration, and public education campaigns are essential to distinguish evidence-based therapies from experimental or fraudulent practices (21). Ethical stewardship must remain a guiding principle as the field of regenerative medicine continues to advance.

6. FUTURE PROSPECTS AND EMERGING TRENDS

6.1 Personalized and Precision Stem Cell Therapy

The future of stem cell therapy is inextricably linked to the paradigm shift toward personalized and precision medicine. By utilizing patient-derived cells, especially induced pluripotent stem cells (iPSCs), therapies can be customized to an individual’s unique genetic and immunological profile. This approach minimizes the risk of immune rejection and enhances therapeutic efficacy. Personalized stem cells also serve as valuable platforms for in vitro disease modeling, enabling the study of pathophysiological mechanisms and individualized drug screening. As genomic and proteomic technologies continue to advance, their integration with stem cell platforms is expected to refine diagnostic accuracy and support the development of highly specific, patient-centered regenerative interventions.

6.2 Integration with Artificial Intelligence and Big Data

The integration of artificial intelligence (AI) and big data analytics is poised to transform the landscape of stem cell research and clinical application. AI-driven algorithms can analyze complex, multidimensional datasets derived from genomics, transcriptomics, and imaging, allowing for precise predictions of stem cell behavior, differentiation pathways, and treatment outcomes. In manufacturing settings, AI can enhance process automation, ensure quality control, and detect anomalies in real time. Moreover, machine learning can facilitate high-throughput screening of bioactive compounds and optimize cell culture protocols. As data ecosystems in biomedicine continue to expand, AI will play a critical role in accelerating discovery, reducing variability, and translating benchside innovations to bedside therapies with greater efficiency.

6.3 Potential for Whole-Organ Regeneration and Transplant Alternatives

One of the most ambitious goals in regenerative medicine is the generation of functional, transplantable organs using stem cells. Although whole-organ bioengineering remains in its infancy, significant progress has been made in developing vascularized tissue constructs and organoids that recapitulate key structural and functional attributes of native organs. Techniques such as decellularized organ scaffolds, 3D bioprinting, and self-organizing organoid systems are being refined to address challenges in tissue complexity, vascular integration, and immune compatibility. In the near future, bioengineered organs may offer viable alternatives to donor transplants, alleviating organ shortages and improving outcomes in end-stage organ failure.

7. CONCLUSION AND RECOMMENDATIONS

7.1 Summary of Key Findings

Stem cell therapy has emerged as a transformative modality in regenerative medicine, offering novel solutions for previously intractable diseases and injuries. Considerable advancements have been made in understanding the classification, biology, and therapeutic potential of various stem cell types, including embryonic, adult, and induced pluripotent stem cells. Clinical applications have demonstrated encouraging results across a wide range of conditions, including hematologic disorders, neurodegenerative diseases, cardiovascular injury, and musculoskeletal degeneration. Technological innovations—such as gene editing, 3D bioprinting, and nanotechnology—have further expanded the scope and precision of stem cell-based interventions.

7.2 Addressing Gaps and Challenges in Current Research

Despite the progress, significant scientific, technical, and ethical challenges remain. Tumorigenic risks associated with pluripotent stem cells, immunological incompatibility in allogeneic transplants, and incomplete understanding of differentiation pathways pose barriers to safe and effective therapy. Moreover, the absence of standardized protocols and regulatory harmonization impedes clinical translation. Ethical concerns related to embryo use, informed consent, and the proliferation of unregulated clinics offering unverified therapies further complicate the field. Addressing these issues requires multidisciplinary collaboration and sustained investment in both foundational and translational research.

7.3 Recommendations for Future Directions and Policy Considerations

To ensure the responsible advancement of stem cell therapies, several strategic measures are recommended. First, rigorous preclinical studies and long-term follow-up in clinical trials are essential to evaluate safety, efficacy, and durability. Second, the development and enforcement of globally harmonized regulatory frameworks will enhance oversight and facilitate international collaboration. Third, investment in Good Manufacturing Practice (GMP) facilities and specialized training programs will support the scale-up of high-quality, reproducible cell-based therapies. Lastly, public engagement and education must be prioritized to promote ethical literacy, build public trust, and mitigate the spread of misinformation. By addressing these critical areas, stem cell therapy can move toward fulfilling its full therapeutic potential, reshaping the future of medicine and offering renewed hope to patients worldwide.

REFERENCES

[1] AstraZeneca. (2024). Collaboration in cell therapy regulation. *AstraZeneca*. Retrieved from https://www.astrazeneca.com/what-science-can-do/topics/next-generation-therapeutics/regulatory-success-cell-therapy.html

[2] Brannigan, R. (2025). Sperm stem cells were used for the first time in an attempt to restore fertility. *WIRED*. Retrieved from https://www.wired.com/story/first-testicular-stem-cell-transplant-in-a-human-patient

[3] Cell. (2024). Past, present, and future of CRISPR genome editing technologies. *Cell*, 186(7), 1-17. Retrieved from https://www.cell.com/cell/fulltext/S0092-8674(24)00111-9

[4] DVC Stem. (2024). Stem cell research controversy: A deep dive. *DVC Stem*. Retrieved from https://www.dvcstem.com/post/stem-cell-research-controversy

[5] Frontiers in Cell and Developmental Biology. (2024). Organoids as complex (bio)systems. *Frontiers in Cell and Developmental Biology*, 12, 1268540. Retrieved from https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1268540/full

[6] Frontiers in Medicine. (2023). Advances in stem cell therapy: New applications and challenges. *Frontiers in Medicine*, 10, 1225551. Retrieved from https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1225551/full

[7] Frontiers in Neuroscience. (2024). Enhancing regenerative medicine: The crucial role of stem cell therapy. *Frontiers in Neuroscience*, 14, 1269577. Retrieved from https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2024.1269577/full

[8] Innovative Genomics Institute. (2024). CRISPR clinical trials: A 2024 update. *Innovative Genomics Institute*. Retrieved from https://innovativegenomics.org/news/crispr-clinical-trials-2024/

[9] Li, Z., Chen, L., Wu, J., Chen, Y., Zhu, Y., Li, G., Xie, G., & Tang, G. (2025). A review of 3D bioprinting for organoids. *Medical Review*. Retrieved from https://www.science.org/doi/10.1126/science.add8593

[10] Liu, C., Zhang, Y., & Wang, X. (2023). CRISPR/Cas9 therapeutics: Progress and prospects. *Signal Transduction and Targeted Therapy*, 8(1), 94. Retrieved from https://www.nature.com/articles/s41392-023-01309-7

[11] Nuffield Council on Bioethics. (2024). Stem cell therapy: The ethical issues. *Nuffield Council on Bioethics*. Retrieved from https://www.nuffieldbioethics.org/publication/stem-cell-therapy-the-ethical-issues/

[12] Orwig, K. E., & Schlatt, S. (2025). Sperm stem cells were used for the first time in an attempt to restore fertility. *WIRED*. Retrieved from https://www.wired.com/story/first-testicular-stem-cell-transplant-in-a-human-patient

[13] PLOS ONE. (2024). The use of artificial intelligence in induced pluripotent stem cell research and therapy. *PLOS ONE*, 19(3), e0302537. Retrieved from https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0302537

[14] PubMed Central. (2023). Advances in three-dimensional bioprinted stem cell-based tissue constructs for regenerative medicine. *Frontiers in Bioengineering and Biotechnology*, 11, 938540. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9385403/

[15] PubMed Central. (2023). Ethical and safety issues of stem cell-based therapy. *Frontiers in Pharmacology*, 8, 176. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765738/

[16] PubMed Central. (2023). Insights on three-dimensional organoid studies for stem cell therapy. *Frontiers in Cell and Developmental Biology*, 11, 10837234. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10837234/

[17] PubMed Central. (2024). Nano delivery systems in stem cell therapy. *Materials Today Bio*, 16, 100402. Retrieved from https://www.sciencedirect.com/science/article/pii/S2790676024000402

[18] PubMed Central. (2024). Organ regeneration through stem cells and tissue engineering. *Frontiers in Cell and Developmental Biology*, 12, 9973391. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9973391/

[19] PubMed Central. (2024). Recent developments and future prospects in stem-cell therapy. *Stem Cell Research & Therapy*, 15(1), 11634165. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634165/

[20] PubMed Central. (2024). Recent advances in CRISPR/Cas9 delivery approaches for stem cell therapy. *Frontiers in Cell and Developmental Biology*, 12, 10661828. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661828/

[21] PubMed Central. (2024). Recent advances in nanomaterials for modulation of stem cell differentiation. *Frontiers in Bioengineering and Biotechnology*, 12, 39194636. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC39194636/